Loading...
We have set up our new Discord server! Share your feedback and find like-minded people! Join our Discord
- Ticker
- MDNA
- Price
- -
- Stock movement down
- -0.01 (-2.95%)
- Company name
- Medicenna Therapeutics Corp
- Exchange
- (NASDAQ ,
- Currency
- USD )
- Sector
- Healthcare >Biotechnology
- Market cap
- 21.29M
- Ent value
- -92.81K
- Price/Sales
- -
- Price/Book
- 0.91
- Div yield
- -
- Div growth
- -
- Growth years
- -
- FCF payout
- -
- Trailing P/E
- -
- Forward P/E
- -
- PEG
- -
- EPS growth
- -
- 1 year return
- -33.25%
- 3 year return
- -60.34%
- 5 year return
- -
- 10 year return
- -
Last updated: 2024-12-17
DIVIDENDS
MDNA does not pay dividends or no data was received
VALUATION
Valuation Ratios
Loading...
Valuation Ratios data
| Trailing P/E | - |
| Price to OCF | - |
| Price to FCF | - |
| Price to EBITDA | - |
| EV to EBITDA | - |
Valuation (Sales/Book Value)
Loading...
Valuation (Sales/Book Value) data
| Price to Sales | - |
| Price to Book | 0.91 |
| EV to Sales | - |
FINANCIALS
Per share
Loading...
Per share data
| Current share count | 69.64M |
| EPS (TTM) | -0.20 |
| FCF per share (TTM) | -0.19 |
Income statement
Loading...
Income statement data
| Revenue (TTM) | 0.00 |
| Gross profit (TTM) | 0.00 |
| Operating income (TTM) | -22.58M |
| Net income (TTM) | -14.07M |
| EPS (TTM) | -0.20 |
| EPS (1y forward) | -0.21 |
Margins
Loading...
Margins data
| Gross margin (TTM) | - |
| Operating margin (TTM) | - |
| Profit margin (TTM) | - |
Balance Sheet
Loading...
Please create a free account or log in to access this chart
Balance Sheet data
| Cash | 25.69M |
| Net receivables | 306.00K |
| Total current assets | 27.68M |
| Goodwill | 0.00 |
| Intangible assets | 59.00K |
| Property, plant and equipment | 0.00 |
| Total assets | 27.74M |
| Accounts payable | 0.00 |
| Short/Current long term debt | 0.00 |
| Total current liabilities | 3.69M |
| Total liabilities | 4.31M |
| Shareholder's equity | 23.44M |
| Net tangible assets | 0.00 |
Cash flow
Loading...
Please create a free account or log in to access this chart
Cash flow data
| Operating cash flow (TTM) | -13.34M |
| Capital expenditures (TTM) | 0.00 |
| Free cash flow (TTM) | -13.34M |
| Dividends paid (TTM) | 0.00 |
Financial returns
Loading...
Please create a free account or log in to access this chart
Financial returns data
| Return on Equity | -60.05% |
| Return on Assets | -50.73% |
| Return on Invested Capital | -60.05% |
| Cash Return on Invested Capital | -56.91% |
STOCK INFORMATION
Downside potential
Loading...
Downside potential data
| MDNA | S&P500 | |
| Current price drop from All-time high | -94.88% | -1.87% |
| Highest price drop | -97.37% | -56.47% |
| Date of highest drop | 1 Nov 2023 | 9 Mar 2009 |
| Avg drop from high | -58.41% | -11.07% |
| Avg time to new high | 78 days | 12 days |
| Max time to new high | 759 days | 1805 days |
COMPANY DETAILS
Marketcap
21.29M
Marketcap category
Small-cap
Description
Medicenna Therapeutics Corp., an immunotherapy company, engages in the development and commercialization of Superkines and empowered Superkines for the treatment of cancer and other diseases. It develops MDNA55, an interleukin- 4 (IL-4) EC for the treatment of recurrent glioblastoma, as well as for brain tumors. The company also develops MDNA11, an enhanced version of IL-2 to activate and proliferate the immune cells needed to fight cancer; MDNA209, an IL-2 antagonist for autoimmune diseases, such as multiple sclerosis and graft versus host disease; MDNA413, a dual IL-4/IL-13 antagonist to treat cancer immunotherapies; and MDNA132, an IL-13 Superkine for solid tumors. In addition, it provides BiSKITs platform to develop designer Superkines by fusing them to other proteins, antibodies, cytokines, or other Superkines. The company is headquartered in Toronto, Canada.
Employees
16
Website
Investor relations
-
SEC filings
CEO
Country
USA
City
Stock type
-
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
Seeking AlphaPress releases
No items found
iO Charts is a Seeking Alpha partner